1. Home
  2. JUNS
  3. JUNS News

Latest JUPITER NEUROSCIENCES INC (JUNS) News on July 13, 2025

Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science
JUNS

GlobeNewswire

16 days ago

Jupiter Neurosciences Unveils Nugevia™ GLO: A Breakthrough in Cellular Skin Health, Backed by Patented Pharmaceutical Science

Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador
JUNS

GlobeNewswire

20 days ago

Jupiter Neurosciences Names Golf Legend Annika Sörenstam as First Nugevia™ Brand Ambassador

Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science
JUNS

GlobeNewswire

a month ago

Jupiter Neurosciences Launches Nugevia™: A Premium Longevity and Performance Supplement Line Grounded in Clinical Science

Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
JUNS

GlobeNewswire

3 months ago

Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter

JUNS

ACCESS Newswire

4 months ago

Alliance Entertainment and Jupiter Neurosciences Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV

Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products
JUNS

GlobeNewswire

4 months ago

Jupiter Neurosciences and Aquanova AG Announce Strategic Collaboration to Develop Longevity and Healthspan Products

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones
JUNS

GlobeNewswire

5 months ago

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

JUNS

MT Newswires

5 months ago

Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules

Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial
JUNS

GlobeNewswire

5 months ago

Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial

JUNS

MT Newswires

5 months ago

Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial
JUNS

GlobeNewswire

5 months ago

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials
JUNS

GlobeNewswire

6 months ago

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering
JUNS

GlobeNewswire

7 months ago

Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

Share on Social Networks: